Global Pleural Diseases Therapeutics Market to Reach USD 9.4 Billion by 2033, Growing at a 6.5% CAGR
Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...
The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.
Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...
Dr Arshad Khanani previews the 2024 American Academy of Ophthalmology Annual Meeting, particularly the retina subspecialty day focusing on wet age-related macular degeneration (AMD), with highlights ...
Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...
In 2023, the market is anticipated to be valued at USD 26.64 Billion, marking a significant starting point for a decade-long ...
In patients with moderate to severe Crohn’s disease, guselkumab showed similar efficacy in both biologic-naive and ...
Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback